Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study

This study is investigating whether performing a bone marrow biopsy in the middle of initial chemotherapy treatment (called induction) can help doctors make better decisions for people newly diagnosed with acute myeloid leukemia (AML — a blood cancer). The goal is to see if mid-treatment biopsy findings change how treatment is managed. **You may be eligible if:** - You are 18 years or older - You have been newly diagnosed with AML (either newly developed or secondary from another blood condition) - You are starting intensive chemotherapy (called 7+3 regimen, with or without additional agents) - Your heart pumping function (ejection fraction) is above 50–55% - Your organ function is adequate for intensive chemotherapy **You may NOT be eligible if:** - You have previously been treated for AML - Your heart function is too low - Your organ function is inadequate for intensive chemotherapy Talk to your doctor to see if this trial is right for you.